Wed, October 4, 2017
Tue, October 3, 2017
Mon, October 2, 2017
Fri, September 29, 2017
Thu, September 28, 2017
Wed, September 27, 2017
Tue, September 26, 2017
Mon, September 25, 2017
Fri, September 22, 2017
Thu, September 21, 2017
Wed, September 20, 2017
Tue, September 19, 2017
Mon, September 18, 2017
Fri, September 15, 2017
Thu, September 14, 2017
Wed, September 13, 2017
Tue, September 12, 2017
Mon, September 11, 2017
Fri, September 8, 2017
Thu, September 7, 2017

David Lebovitz Maintained (ALNY) at Hold with Increased Target to $101 on, Sep 21st, 2017


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-101-on-sep-21st-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $50 to $101 on, Sep 21st, 2017.

David has made no other calls on ALNY in the last 4 months.



There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 0 agree with David's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with David


  • Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $99 on, Friday, September 8th, 2017

Publication Contributing Sources